Back to top
more

Capricor Therapeutics (CAPR)

(Delayed Data from NSDQ)

$6.10 USD

6.10
503,316

+0.11 (1.84%)

Updated May 28, 2024 04:00 PM ET

After-Market: $6.10 0.00 (0.00%) 5:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CAPR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Capricor Therapeutics, Inc. [CAPR]

Reports for Purchase

Showing records 61 - 80 ( 82 total )

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 61

08/16/2016

Company Report

Pages: 6

Looking Ahead to ALLSTAR; Exosome Product Heading Into the Clinic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 62

08/16/2016

Company Report

Pages: 7

2Q16 Results; Interesting Times They''re A Comin

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 63

08/01/2016

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 64

08/01/2016

Company Report

Pages: 13

Visions of Exosomes Danced In Their Heads; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 65

07/06/2016

Company Report

Pages: 8

Assuming Coverage With a Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 66

06/16/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 67

06/16/2016

Company Report

Pages: 9

DYNAMIC Benefits Maintained at 12 Months; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 68

06/15/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 69

06/15/2016

Company Report

Pages: 41

Ya Gotta Have Heart; And CAP-1002; Initiating Coverage at Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 100.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 70

03/21/2016

Company Report

Pages: 7

ALLSTAR Resized as Management Anticipates Large Effect Size; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 71

03/02/2016

Daily Note

Pages: 3

Time for a Different Approach in Duchenne Muscular Dystrophy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 72

11/13/2015

Company Report

Pages: 9

3Q15 Update: DYNAMIC Validation of CAP-1002 as Hearty Regenmed

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 73

11/10/2015

Daily Note

Pages: 3

DYNAMIC Results Consistent with Active Regenerative Effect in Failing Hearts

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 74

10/13/2015

Industry Report

Pages: 7

Highlights from the Meeting on the Mesa: Looking Beyond Stem Cells in Regenerative Medicine

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 75

08/14/2015

Company Report

Pages: 10

2Q15 Update-Reiterating Buy Rating with Wholehearted Enthusiasm; DMD Trial Slated for Fall Initiation

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 76

06/09/2015

Daily Note

Pages: 3

FDA Clears HOPE-DUCHENNE Protocol - Trial Could Initiate in September

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 77

05/15/2015

Company Report

Pages: 11

1Q15 Update-Interim ALLSTAR Analysis Planned; Cenderitide and DYNAMIC Data Coming in 2H15

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 78

03/19/2015

Company Report

Pages: 12

4Q14 Update-Cardiac Regeneration with an ALLSTAR Cast; Raising PT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 79

03/05/2015

Daily Note

Pages: 3

Highlights from Meeting with Management-Progress in Cenderitide and DMD Programs

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 80

01/26/2015

Daily Note

Pages: 3

Cash Infusion for Coronary Infusions-High HOPE for a DYNAMIC Start to 2015

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party